This company has been marked as potentially delisted and may not be actively trading. Sage Therapeutics (SAGE) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock Get the Latest News and Ratings for SAGE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sage Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SAGE Analyst Ratings Over TimeTypeCurrent Forecast9/3/24 to 9/3/251 Month Ago8/4/24 to 8/4/253 Months Ago6/5/24 to 6/5/251 Year Ago9/4/23 to 9/3/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)2 Buy rating(s)1 Buy rating(s)Hold13 Hold rating(s)14 Hold rating(s)14 Hold rating(s)16 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)2 Sell rating(s)Consensus Price Target$7.85$8.02$8.87$16.06Forecasted Upside-9.56% Downside-7.66% Downside30.78% Upside103.02% UpsideConsensus RatingReduceReduceHoldReduce SAGE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History SAGE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Sage Therapeutics Stock vs. The CompetitionTypeSage TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 1.93 2.78 2.53Consensus RatingReduceModerate BuyModerate BuyPredicted Upside-9.56% Downside16,147.76% Upside11.15% UpsideNews Sentiment RatingNeutral NewsSee Recent SAGE NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails7/8/2025Scotiabank4 of 5 starsGeorge FarmerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.20+0.33%6/20/2025Robert W. Baird2 of 5 starsJoel BeattySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost TargetNeutral ➝ Neutral$7.00 ➝ $9.00-1.59%6/17/2025Piper Sandler2 of 5 starsDavid AmsellemSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.50-6.54%6/17/2025Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingJoon LeeSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet TargetHold ➝ Hold$8.00 ➝ $9.00-0.72%6/17/2025HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDouglas TsaoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$12.00+32.38%6/17/2025Canaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSumant KulkarniSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost TargetHold ➝ Hold$8.00 ➝ $8.50-6.28%6/16/2025Needham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingAmi FadiaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/11/2025Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageUnderperform$5.00-29.73%2/12/2025WedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLaura ChicoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00-17.13%12/16/2024Stifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetHold ➝ Hold$10.00 ➝ $6.00+11.32% Get the Latest News and Ratings for SAGE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/21/2024TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingR. BaralSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetHold ➝ Hold$10.00 ➝ $9.00+79.28%11/21/2024Royal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingB. AbrahamsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Sector Perform$4.00 ➝ $4.00-18.53%10/30/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetMarket Perform ➝ Market Perform$9.00 ➝ $8.00+17.65%10/10/2024Raymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. BrillSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform8/6/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$12.00 ➝ $10.00+15.21%7/26/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$19.00 ➝ $11.00+1.95%7/19/2024MizuhoSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$18.00 ➝ $16.00+31.47%5/29/2024Baird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. BeattySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/29/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageSell$8.00-32.94%2/28/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetEqual Weight ➝ Equal Weight$20.00 ➝ $22.00+0.09%12/12/2023Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageHold$21.00+4.90%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:56 PM ET. SAGE Forecast - Frequently Asked Questions What is Sage Therapeutics' forecast for 2025? According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Sage Therapeutics is $7.85, with a high forecast of $12.00 and a low forecast of $4.00. Should I buy or sell Sage Therapeutics stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There is currently 1 sell rating and 13 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" SAGE shares. Does Sage Therapeutics's stock price have much downside? According to analysts, Sage Therapeutics's stock has a predicted downside of -9.56% based on their 12-month stock forecasts. Has Sage Therapeutics been downgraded by Wall Street analysts recently? Over the previous 90 days, Sage Therapeutics's stock had 2 downgrades by analysts. What analysts cover Sage Therapeutics? Sage Therapeutics has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, Needham & Company LLC, Piper Sandler, Robert W. Baird, Scotiabank, and Truist Financial in the past 90 days. Do Wall Street analysts like Sage Therapeutics more than its competitors? Analysts like Sage Therapeutics less than other "medical" companies. The consensus rating for Sage Therapeutics is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SAGE compares to other companies. Stock Forecasts and Research Tools Related Companies IDEAYA Biosciences Stock Forecast Ocular Therapeutix Stock Forecast Harmony Biosciences Stock Forecast Disc Medicine Stock Forecast CG Oncology Stock Forecast Recursion Pharmaceuticals Stock Forecast ANI Pharmaceuticals Stock Forecast Adaptive Biotechnologies Stock Forecast Belite Bio Stock Forecast Dyne Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:SAGE) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
